公开(公告)号：US11958907B2

公开(公告)日：2024-04-16

申请号：US17009817

申请日：2020-09-02

Applicant: INNATE PHARMA

Inventor： Ivan Perrot ,  Carine Paturel ,  Laurent Gauthier

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2896 ,  C07K16/30 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US11377492B2

公开(公告)日：2022-07-05

申请号：US16478863

申请日：2018-01-22

Applicant: INNATE PHARMA

Inventor： Nadia Anceriz ,  Mathieu Blery ,  Laurent Gauthier ,  Carine Paturel

IPC: C07K16/30 ,  A61P35/00 ,  C07K16/28 ,  A61K47/68 ,  G01N33/569

Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

公开(公告)号：US10676523B2

公开(公告)日：2020-06-09

申请号：US15511792

申请日：2015-09-15

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Caroline Soulas ,  Nicolaï Wagtmann

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20190218308A1

公开(公告)日：2019-07-18

申请号：US16370726

申请日：2019-03-29

Applicant: INNATE PHARMA

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/40 ,  A61P35/00 ,  G01N33/574 ,  C07K16/28 ,  A61K9/00

CPC classification number: C07K16/2896 ,  A61K39/001154 ,  A61K2039/507 ,  A61K2039/545 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/92 ,  C12N9/14

Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.